2005
|
Sign up to set email alerts
|

Abstract: The importance of the MAP kinase pathway, which includes the kinases Raf, MEK1/2, and ERK1/2, for the proliferation and survival of tumor cells recently increased with the discovery of activating BRAF mutations in human tumors. Therefore, in addition to a role in controlling tumors with Ras mutations and activated growth factor receptors, inhibitors of Raf kinase may harbor therapeutic potential in tumors carrying a BRAF oncogene. A variety of agents have been discovered to interfere with Raf kinase, including… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
24
0

Year Published

2006
2006
2009
2009

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 36 publications
(24 citation statements)
references
References 56 publications
(71 reference statements)
0
24
0
Order By: Relevance
“…11 However, the detailed mechanism of this action exerted by sorafenib remains elusive. Despite the originally functional attribute of sorafenib is designated for its multi-kinase inhibitory actions via blocking kinase-based signal transduction pathways, [12][13][14][15][16] yet, very little is known about whether or not sorafenib can also trigger the apoptotic cancer cell death via activating an alternative pathway. Recently, a report indicated that sorafenib could provoke an apoptotic cell death of human leukemia U937, Jurkat and K562 cells via a mechanism involving an ER-mediated alteration of calcium (Ca 2+ ) homeostasis, yet, the detailed cascade of events that led to the occurrence of apoptotic cell death remains elusive.…”
Section: Resultsmentioning
confidence: 99%
“…11 However, the detailed mechanism of this action exerted by sorafenib remains elusive. Despite the originally functional attribute of sorafenib is designated for its multi-kinase inhibitory actions via blocking kinase-based signal transduction pathways, [12][13][14][15][16] yet, very little is known about whether or not sorafenib can also trigger the apoptotic cancer cell death via activating an alternative pathway. Recently, a report indicated that sorafenib could provoke an apoptotic cell death of human leukemia U937, Jurkat and K562 cells via a mechanism involving an ER-mediated alteration of calcium (Ca 2+ ) homeostasis, yet, the detailed cascade of events that led to the occurrence of apoptotic cell death remains elusive.…”
Section: Resultsmentioning
confidence: 99%
“…In addition, the BRAFV600E mutation also represents a molecular marker for papillary thyroid carcinoma, ovarian serous carcinoma and for a subgroup of colorectal carcinomas. 32 Since the clinical and preclinical testing of BRAF inhibitors for treatment is currently actively ongoing, 33 the availability of a blood test determining BRAF status in tumors may also become useful for the prescription of BRAF inhibitor target therapy.…”
Section: Discussionmentioning
confidence: 99%
“…19), and small-molecule RAF inhibitors. Among the latter, BAY 43-9006 is a bis-aryl urea that inhibits wild-type and BRAF V600E kinase activity in vitro that is presently in phase 2 clinical trials for various cancer types.…”
mentioning
confidence: 99%